These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27665049)

  • 1. Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma.
    He J; Liu Y
    EBioMedicine; 2016 Oct; 12():4-5. PubMed ID: 27665049
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
    Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study.
    Watanabe Y; Iwamura A; Shimada YJ; Wakai K; Tamakoshi A; Iso H;
    EBioMedicine; 2016 Oct; 12():68-71. PubMed ID: 27614396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
    El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
    Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
    Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
    Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma tumour markers: current role and expectations.
    Rich N; Singal AG
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):843-53. PubMed ID: 25260312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.
    Shehata F; Abdel Monem N; Sakr M; Kasem S; Balbaa M
    Med Oncol; 2013; 30(3):673. PubMed ID: 23912699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores.
    Dituri F; Serio G; Filannino D; Mascolo A; Sacco R; Villa E; Giannelli G
    Cancer Lett; 2014 Oct; 353(2):264-71. PubMed ID: 25088578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment.
    Trojan J; Raedle J; Zeuzem S
    Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased Serum Endoglin and Transforming Growth Factor β1 mRNA Expression and Risk of Hepatocellular Carcinoma in Cirrhotic Egyptian Patients.
    Teama S; Fawzy A; Teama S; Helal A; Drwish AD; Elbaz T; Desouky E
    Asian Pac J Cancer Prev; 2016; 17(5):2429-34. PubMed ID: 27268609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
    Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
    Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia.
    Yasmin Anum MY; Looi ML; Nor Aini AH; Merican I; Wahidah A; Mohd Radzi AH; Nor Azizah A; Othman NH
    Med J Malaysia; 2009 Sep; 64(3):223-7. PubMed ID: 20527273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and detection of hepatocellular carcinoma.
    Simpson HN; McGuire BM
    Clin Liver Dis; 2015 May; 19(2):295-307. PubMed ID: 25921664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Golgi Phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.
    Li X; Wu K; Fan D
    Hepatology; 2009 Jul; 50(1):325. PubMed ID: 19492428
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma.
    Yang XR; Guo W
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):529-530. PubMed ID: 30519762
    [No Abstract]   [Full Text] [Related]  

  • 16. Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas.
    Riener MO; Stenner F; Liewen H; Hellerbrand C; Bahra M; Kristiansen G
    Hepatology; 2009 Jul; 50(1):326. PubMed ID: 19496179
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients.
    Radwan MI; Pasha HF; Mohamed RH; Hussien HI; El-Khshab MN
    Cytokine; 2012 Oct; 60(1):271-6. PubMed ID: 22682513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Hepatocellular Carcinoma (HCC): An Update.
    Li D; Satomura S
    Adv Exp Med Biol; 2015; 867():179-93. PubMed ID: 26530367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization.
    Shoreibah MG; Bloomer JR; McGuire BM; Massoud OI
    Am J Med Sci; 2014 May; 347(5):415-9. PubMed ID: 24759379
    [No Abstract]   [Full Text] [Related]  

  • 20. [Are alpha-fetoprotein and other markers useful in the diagnosis and prognosis of hepatocellular carcinoma?].
    Forner A; Liccioni A; Reig ME
    Gastroenterol Hepatol; 2014 Jan; 37(1):17-20. PubMed ID: 24332662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.